Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.
Glatiramer acetate (GA), represents an established treatment of relapsing/remitting multiple sclerosis (MS). The mechanisms responsible for the effect of GA are not fully understood. We generated GA-, myelin basic protein (MBP)- and purified protein derivative (PPD)-specific T cell lines from three MS patients and one healthy donor. The GA-specific lines were CD3+, CD4+, CD8- and produced tumor-necrosis-factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-4 (IL-4), interleukin-6 (IL-6) and interleukin-10 (IL-10) after stimulation with GA in the presence of irradiated peripheral blood mononuclear cells. MBP-specific T cell lines showed an identical phenotype and secreted TNF-alpha, IFN-gamma, IL-4, IL-10, but not IL-6. Co-culture experiments demonstrated, that GA-specific T cell lines have the capability to suppress the proliferation of MBP-specific T cell lines.
Dabbert
D
D
Department of Neurology, Georg-August-University, Göttingen, Germany.
Rösner
S
S
Krämer
M
M
Schöll
U
U
Tumani
H
H
Mäder
M
M
Weber
F
F
D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002460:Cell Line / Q000187:drug effects* / Q000276:immunology / Q000528:radiation effects; D016207:Cytokines / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D004676:Myelin Basic Protein / Q000276:immunology*; D010455:Peptides / Q000494:pharmacology*; D010641:Phenotype; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000528:radiation effects
D016207:Cytokines; D007166:Immunosuppressive Agents; D004676:Myelin Basic Protein; D010455:Peptides; D000068717:Glatiramer Acetate